Immuno Oncology Assays Market Report 2026

Immuno Oncology Assays Market Overview

• Immuno Oncology Assays market size has reached to $4.88 billion in 2025 • Expected to grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 12.7% • Growth Driver: Rising Prevalence Of Cancer Cases Driving Growth In The Market Due To Increasing Tobacco And Alcohol Consumption • Market Trend: Advancements In Liquid Biopsy Strengthen Immunotherapy Response Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immuno Oncology Assays Market?

Immuno-oncology assays are laboratory tests used to evaluate immune system responses against cancer by measuring biomarkers, immune cell activity, cytokines, gene expression, and other tumor-related parameters. These assays enable researchers and clinicians to study cancer immunotherapies, assess treatment efficacy, identify predictive biomarkers, and support the development of personalized cancer treatment strategies. The main product types of immuno oncology assays include consumables and software. Consumables refer to assay reagents, kits, and other laboratory materials used for detecting, analyzing, and monitoring immune-related biomarkers associated with cancer therapies. These assays utilize technologies such as polymerase chain reaction, immunoassay, next generation sequencing, in situ hybridization, and flow cytometry and are used for indications including lung cancer, breast cancer, colorectal cancer, bladder cancer, melanoma, and other indications. The various applications involved are cancer diagnosis, therapeutic monitoring, patient stratification, and clinical trials and they are utilized by end users including hospitals and clinics, academic and research institutes, and others.

What Is The Immuno Oncology Assays Market Growth Forecast?

The immuno oncology assays market size is expected to see rapid growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to rising demand for advanced immune profiling assays, increasing adoption of precision oncology strategies, growing development of novel cancer immunotherapies, expanding use of predictive biomarkers for treatment selection, increasing collaborations between pharmaceutical companies and research institutions. Major trends in the forecast period include increasing adoption of multiplex immuno oncology assays for comprehensive biomarker analysis, rising demand for companion diagnostics in cancer immunotherapy development, growing focus on immune profiling for personalized oncology treatment strategies, increasing utilization of biomarker based clinical trial approaches, rising demand for advanced assay platforms supporting rapid cancer research workflows.

What Is The Driver Of The Immuno Oncology Assays Market?

The rising prevalence of cancer cases is expected to propel growth of the immuno-oncology assays market going forward. Cancer cases refer to the number of individuals diagnosed with any form of cancer within a specific population, region, or time, serving as a key indicator for assessing disease burden and healthcare needs. The rising prevalence of cancer cases is due to increasing tobacco and alcohol consumption, as these habits expose individuals to carcinogenic substances that damage cells, increase genetic mutations, and significantly elevate the risk of developing various cancers, including lung, liver, oral, and esophageal cancers. Immuno-oncology assays enable cancer diagnosis and treatment by identifying tumor-specific biomarkers, evaluating immune responses, guiding personalized immunotherapy selection, and monitoring treatment effectiveness. For instance, in January 2026, according to the Centers for Disease Control and Prevention, a US-based public health agency, the United States recorded approximately 1.85 million new cancer cases in 2022, while cancer accounted for 613,349 deaths in 2023. Therefore, the rising prevalence of cancer cases is driving growth of the immuno-oncology assays market.

Key Players In The Global Immuno Oncology Assays Market

Major companies operating in the immuno oncology assays market are Thermo Fisher Scientific Inc, F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Merck KGaA, Labcorp Holdings Inc, Agilent Technologies Inc, Sysmex Corporation, Illumina Inc, Revvity Inc, Charles River Laboratories International Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Bruker Corporation, Natera Inc, Tempus AI Inc, Promega Corporation, Guardant Health Inc, NeoGenomics Inc, Bio-Techne Corporation, Myriad Genetics Inc, Adaptive Biotechnologies Corporation

Global Immuno Oncology Assays Market Trends and Insights

Major companies operating in the immuno-oncology assays market are focusing on developing innovative solutions, such as liquid biopsy immunotherapy response monitoring assays, to enhance early treatment response assessment, optimize therapeutic decision-making, and improve precision oncology outcomes. Liquid biopsy immunotherapy response monitoring assays are molecular diagnostic tests that analyze circulating tumor DNA (ctDNA) from blood samples to evaluate how patients respond to immune checkpoint inhibitor therapies over time, providing a less invasive and earlier alternative to conventional imaging-based assessments while enabling clinicians to detect molecular changes before clinical disease progression becomes apparent. For instance, in June 2025, Tempus AI Inc., a US-based precision medicine company, launched xM for Treatment Response Monitoring (TRM), a liquid biopsy assay designed to monitor molecular response to immune checkpoint inhibitor therapy in patients with advanced solid tumors. The assay quantifies changes in circulating tumor DNA using a multi-parametric algorithm that integrates copy number variations and somatic and germline variant allele frequencies to estimate circulating tumor fraction with high sensitivity. It enables clinicians and researchers to detect molecular response before six weeks of treatment, facilitating earlier therapeutic interventions and refined treatment strategies. Initially introduced for research use, the assay expands Tempus’ molecular monitoring portfolio for immuno-oncology and is expected to become clinically available following its research deployment.

What Are Latest Mergers And Acquisitions In The Immuno Oncology Assays Market?

In July 2025, Quanterix Corporation, a US-based healthcare technology company, acquired Akoya Biosciences Inc. for an undisclosed amount. With this acquisition, Quanterix aims to create the first integrated platform capable of measuring biomarkers across the blood and tissue continuum, strengthening its position in precision medicine and expanding its capabilities in oncology, neurology, and immunology research. Akoya Biosciences Inc. is a US-based healthcare technology company that specializes in providing immuno oncology (IO) assays and validated IO-focused panels for spatial biology and tissue-based biomarker analysis.

What Defines the Immuno Oncology Assays Market?

The immuno-oncology assays market consists of revenues earned by entities by providing services such as biomarker testing and analysis, immune profiling services, companion diagnostic testing, clinical trial assay services, and cancer immunotherapy response monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The immuno-oncology assays market also includes sales of immuno-oncology assay kits, flow cytometry reagents, multiplex immunoassay panels, and antibody reagents and detection kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immuno Oncology Assays Market Report 2026?

The immuno oncology assays market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immuno oncology assays industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.